The global cell culture media bags market size was valued at USD 1.50 billion in 2025 and is projected to grow from USD 1.61 billion in 2026 to USD 2.82 billion by 2034, registering a CAGR of 7.25% during the forecast period (2026-2034). North America dominated the cell culture media bags market with a share of 37.82% in 2025.
Cell culture media bags are sterile, single-use containers designed for the storage, transfer, and handling of cell culture media in biopharmaceutical manufacturing. They are used in bioreactors, vaccine production, and cell therapy manufacturing. Cell culture media bags are classified under HSN Code 3926.90 and SIC Code 2673 (plastics, foil, and coated paper bags).
The cell culture media bags market demand is driven by increasing biopharmaceutical production, adoption of single-use bioprocessing systems, and expanding vaccine manufacturing activities. Rising investments in cell and gene therapy manufacturing and demand for contamination-free media handling support cell culture media bags market growth.
Download a Free Sample To learn more about this report,
Preference for Low-Extractable Polymer Films
The cell culture media bags market analysis shows increasing preference for specialized polymer films with low extractable and leachable levels. Manufacturers are focusing on film compatibility, material consistency, and validated product-contact surfaces. For instance, Thermo Fisher Scientific offers Gibco universal media bags with ultralow-density polyethylene contact layers and low extractable and leachable profiles.
Adoption of Customized Closed-System Media Bags
Biopharmaceutical companies require specific bag volumes, sterile connectors, and tubing configurations for different production stages. This trend is encouraging suppliers to develop application-specific designs that support media preparation and transfer. The availability of flexible configurations also helps manufacturers reduce manual handling and maintain process consistency across production batches.
Supply chain disruptions are expected to have a moderate impact on the cell culture media bags market share due to shortages of medical-grade polymer films, sterile connectors, and tubing materials. The market is expected to experience a K-shaped recovery, as established manufacturers with integrated production facilities can restore supply faster than smaller suppliers. Limited sterilization capacity and longer delivery periods may further affect production. The market is projected to grow at a CAGR of 7.25%. Supply chain constraints could approximately lower this by 1 percentage point, resulting in short-term growth of around 6.25%. Improved material availability and production capacity are expected to support recovery toward 7.25%.
The cell culture media bags market forecasts continued investment in single-use manufacturing capacity and bioprocessing technologies.
Key Investment and Funding Activities in Cell Culture Media Bags Market, 2025–2026
Expansion of Cell Therapy Manufacturing and Demand for Pre-Filled Cell Culture Media Bags Drives Market
Development of cell and gene therapies is strengthening demand for sterile cell culture media bags. These bags support controlled media storage and transfer during cell expansion processes. According to the U.S. FDA, regenerative medicine advanced therapy designation requests increased from 59 in 2024 to 91 in 2025. This expanding development activity is encouraging manufacturers to adopt reliable single-use media handling solutions for clinical and commercial manufacturing.
Preference for ready-to-use cell culture media is increasing demand for pre-filled sterile media bags. Biopharmaceutical manufacturers are adopting these bags to reduce in-house media preparation and improve production efficiency. Pre-filled formats also simplify media handling and support consistent manufacturing operations. For instance, Cytiva supplies HyClone liquid cell culture media in presterilized container bags ranging from 1 to 1,000 liters, supporting different bioprocessing requirements.
Extractables and Leachables Concerns and Limited Compatibility with Existing Bioprocessing Equipment Restrain Market Growth
Potential release of chemical compounds from polymer films presents a major challenge for cell culture media bags. Prolonged contact between culture media and plastic surfaces may introduce substances that affect media quality or cell growth. These qualification requirements increase testing costs and extend implementation periods, particularly for sensitive cell therapy manufacturing processes.
The lack of standardized connections between cell culture media bags and existing bioprocessing equipment presents a significant market restraint. Differences in tubing dimensions and connector designs can limit compatibility across suppliers. Additional qualification procedures increase implementation costs and delay equipment integration.
Integration of Automated Bag Integrity Testing and Development of Sensor-Compatible Media Mixing Bags Creates New Growth Opportunities
Advancements in automated integrity testing create opportunities for manufacturers to supply bags compatible with advanced leak detection systems. These technologies help identify defective seals before sterile media transfer, reducing contamination risks. For instance, Sartorius offers point-of-use leak testing for bags up to 2,000 liters through its Sartocheck 5 Plus Universal system with compatible accessories.
The integration of monitoring sensors into single-use media preparation bags offers opportunities for advanced bioprocessing applications. Sensor-compatible bags allow manufacturers to monitor pH and conductivity during media preparation without repeated manual sampling. These capabilities support controlled mixing and improve process consistency. The availability of automated single-use mixing systems is creating opportunities for bag suppliers to develop compatible designs for pharmaceutical manufacturing facilities.
In 2025, 2D Bags had a share of 43.50%, supported by increasing demand for cost-effective disposable media bags in biopharmaceutical manufacturing. Its established use in sterile fluid storage supports widespread adoption across bioprocessing facilities.
3D Bags are likely to witness a CAGR of 8.65% during the forecast period. This growth is attributed to increasing demand for bulk media storage in commercial biomanufacturing. Their expandable structure supports higher filling volumes and efficient container utilization.
Request Customizationto receive a tailored report.
EVA dominated the material segment in 2025, accounting for a share of 32.50%. This dominance is driven by increasing demand for cost-effective disposable media bags in biopharmaceutical manufacturing. Its established use in sterile fluid storage and suitability for heat-sealed bag manufacturing support segment growth
The fluorinated polymers segment is projected to undergo growth at a CAGR of 9.25% during the forecast period due to rising demand for chemically resistant media storage materials. Growing requirements for low-extractable contact surfaces in sensitive bioprocessing applications support segment growth.
5–50 L dominated the capacity segment with a share of 33.80% in 2025, driven by frequent media preparation in pilot-scale bioprocessing. Its manageable capacity suits repeated small-batch operations and reduces excess media storage during process development activities.
>500 L is estimated to register a growth rate of 14.50% during the forecast period, owing to increasing commercial-scale media handling requirements. Large-capacity bags support centralized media preparation and reduce container changeovers during high-volume biopharmaceutical production.
By end user, the pharmaceutical & biotechnology companies segment accounted for a dominant share of 48.50% in 2025. This growth is driven by increasing production of monoclonal antibodies and cell-based therapies. Growing demand for sterile media storage during cell expansion supports segment growth.
CROs & CDMOs are expected to achieve a growth rate of 8.55% during the forecast period due to increasing outsourcing of biologics development and manufacturing. Rising demand for client-specific media preparation and frequent production changeovers across multiple biopharmaceutical projects support segment growth.
Speak to an Analystto discuss market opportunities.
The North America cell culture media bags market accounted for the largest regional share of 37.82% in 2025.
FDA guidance introduced greater flexibility in chemistry, manufacturing, and control requirements for advanced therapies. These regulatory developments could encourage additional manufacturing activity. Growing demand for qualified single-use media containers and expansion of commercial cell therapy production are expected to support market growth.
Canadian government announced funding of up to USD 1.97 million for STEMCELL Technologies to establish custom cell culture media manufacturing capacity. This development is expected to strengthen domestic bioprocessing supply chains and create additional demand for sterile media storage solutions.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cell culture media bags market is expected to grow at a CAGR of 9.04% during the forecast period, showcasing the fastest-growing regional market.
China benefits from expanding CAR-T cell therapy manufacturing and increasing domestic biopharmaceutical production capacity. AstraZeneca's planned commercial cell therapy manufacturing facility in Shanghai's Lin-gang Special Area is expected to strengthen local CAR-T production capabilities in 2026. Growing investments in advanced therapy manufacturing and increasing requirements for contamination-free cell culture processes are expected to support demand for sterile media storage and transfer bags.
India’s BioE3 Policy targets high-performance biomanufacturing, with a national goal of building a USD 300 billion bioeconomy by 2030. As part of implementation, the Department of Biotechnology and BIRAC are establishing shared biofoundries and biomanufacturing hubs to support pilot and pre-commercial scale-up, including precision biotherapeutics and next-generation cell and gene therapies.
Japan Agency for Medical Research and Development (AMED) selected projects focus on next-generation manufacturing technologies for regenerative medicine and cell therapies, including a fully closed automated cell culture bag platform with image-based quality assessment led by Yokogawa Electric and an automated culture system for expanding induced pluripotent stem cells led by Terumo. These projects target greater automation, process consistency, and quality control in cell manufacturing.
The Europe cell culture media bags market is projected to grow at a CAGR of 6.65% during the forecast period.
UK Government’s Life Sciences Sector Plan, updated in July 2026, aims to make the UK Europe’s leading life sciences economy by 2030 and includes targets to increase commercial research and development investment and life sciences manufacturing capacity. The government’s Life Sciences Innovative Manufacturing Fund, which remains open for eligible applications until March 2030, provides up to USD 700 million in capital grants for manufacturing investments in medicines and medical technologies.
Germany has an expanding biologics manufacturing capacity and increasing demand for advanced cell therapy production. The country's established biopharmaceutical industry includes major manufacturers such as Boehringer Ingelheim and Sartorius, which support large-scale biologics manufacturing and single-use bioprocessing technologies.
The Latin America cell culture media bags market is expected to grow at a CAGR of 7.35% during the forecast period. Brazil is expanding its cell therapy manufacturing infrastructure through the Ministry of Health and Fiocruz. This initiative is expected to increase demand for sterile media bags used in cell expansion and controlled media transfer.
Mexico is strengthening domestic biotechnology manufacturing through Plan México. The Autonomous University of Nuevo León has received COFEPRIS authorization for a clinical trial involving locally manufactured CAR-T cells. The university's integrated cell processing capabilities are expected to support demand for small-volume cell culture media bags used in clinical-scale manufacturing.
The Middle East & Africa cell culture media bags market is expected to grow at a CAGR of 7.15% during the forecast period. The UAE is advancing cell therapy manufacturing through specialized facilities such as the Abu Dhabi Stem Cells Center. The center has developed clinical-grade induced pluripotent stem cells using GMP-compliant processes.
South Africa is strengthening domestic vaccine manufacturing through Biovac's expanded production infrastructure in Cape Town. The facility is expected to reach an annual manufacturing capacity of 30–40 million vaccine doses upon completion. Expansion of vaccine production and upstream bioprocessing activities is expected to create opportunities for sterile cell culture media bags.
The cell culture media bags market competitive landscape is moderately consolidated, with competition among global bioprocessing manufacturers and specialized single-use bag suppliers. Key players such as Thermo Fisher Scientific, Sartorius AG, Cytiva, Merck KGaA, and Corning are estimated to hold 55% of the global cell culture media bags market share.
Established manufacturers compete through advanced polymer films and strong distribution networks. Emerging players in the cell culture media bags market ecosystem, such as Technoflex and Shanghai LePure Biotech, compete through customized bag designs and competitive pricing.
October 2026: Repligen Corporation completed its acquisition of BioLife Solutions, expanding its cell therapy portfolio with biopreservation media and cell processing technologies.
September 2026: Sartorius Stedim Biotech reported manufacturing expansion at its M'Hamdia facility in Tunisia.
July 2025: Repligen Corporation launched ProConnex MixOne, a single-use mixing system integrating technologies from its fluid management portfolio for biopharmaceutical processing.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Biosensors Market Size, Share, Growth, Analysis, Report, 2034
B Cell Lymphoma Treatment Market Size, Share, Growth, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Organoids Market Size, Share, Growth, Analysis, Report, 2034
Cell Line Development Services Market Size, Share, 2034
Centrifuge Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com